Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» biosimilars
biosimilars
Coherus hits FDA hurdles for PD-1 drug, Neulasta biosimilar on-body injector
Coherus hits FDA hurdles for PD-1 drug, Neulasta biosimilar on-body injector
Fierce Pharma
Coherus Biosciences
Neulasta
biosimilars
FDA
Junshi Biosciences
Flag link:
Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar
Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar
BioSpace
Alvotech
FDA
biosimilars
AVT02
AbbVie
Humira
Flag link:
Alvotech gets new FDA review for Humira biosimilar
Alvotech gets new FDA review for Humira biosimilar
BioPharma Dive
Alvotech
FDA
Humira
biosimilars
Flag link:
Save billions or stick with Humira? Drug brokers steer Americans to the costly choice
Save billions or stick with Humira? Drug brokers steer Americans to the costly choice
Medical Marketing and Media
PBMs
biosimilars
Humira
Flag link:
FDA revises biosimilar guidelines for clearer drug labelling
FDA revises biosimilar guidelines for clearer drug labelling
Pharmaceutical Technology
FDA
biosimilars
labeling
Flag link:
Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara
Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara
BioSpace
Sandoz
Samsung Bioepis
biosimilars
JNJ
Stelara
Flag link:
AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report
AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report
BioSpace
AbbVie
Humira
biosimilars
Crohn's Disease
Flag link:
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Motley Fool
Novartis
biosimilars
Eylea
Flag link:
Novartis updates on Sandoz finances ahead of spin-off
Novartis updates on Sandoz finances ahead of spin-off
Pharmaphorum
Novartis
Sandoz
spinoffs
generics
biosimilars
Flag link:
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Biogen
Sandoz
FDA
biosimilars
MS
multiple sclerosis
Tysabri
Flag link:
CVS Health Enters Biosimilars Market with Launch of Cordavis Subsidiary
CVS Health Enters Biosimilars Market with Launch of Cordavis Subsidiary
BioSpace
CVS Health
biosimilars
Cordavis
Flag link:
Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation
Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation
Biopharma Reporter
Novartis
Sandoz
spinoff
biosimilars
generics
Flag link:
Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4
Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4
Fierce Pharma
Novartis
Sandoz
spinoffs
generics
biosimilars
Flag link:
Sandoz plans to enter the Eylea biosimilar race
Sandoz plans to enter the Eylea biosimilar race
Clinical Trials Arena
Sandoz
generics
biosimilars
Eylea
Novartis
wet age-related macular degeneration
Flag link:
What’s Next In Biologics? Biosimilar Expert Predicts Big Fall Changes
What’s Next In Biologics? Biosimilar Expert Predicts Big Fall Changes
Forbes
biologics
biosimilars
legislation
Flag link:
Amgen's hyped Humira biosimilar fritters away its exclusivity advantage
Amgen's hyped Humira biosimilar fritters away its exclusivity advantage
Fierce Pharma
Amgen
AbbVie
biosimilars
Humira
Flag link:
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Fierce Pharma
Biogen
biosimilars
M&A
Samsung Bioepis
Flag link:
Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance
Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance
Fierce Pharma
AbbVie
earnings
Humira
biosimilars
Imbruvica
Flag link:
Biosimilar makers split strategies in bid to take on top-selling Humira
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
Flag link:
Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment
Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment
Fierce Pharma
Teva Pharmaceutical
Alvotech
biosimilars
Humira
AbbVie
drug manufacturing
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »